{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:38:43Z","timestamp":1791362323833,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Canine malignant melanoma is highly aggressive and generally chemoresistant. Toceranib is a kinase inhibitor drug that inhibits several tyrosine kinases including the proto-oncogene receptor tyrosine kinase KIT. Although canine malignant melanoma cells often express KIT, a therapeutic effect for toceranib has yet to be reported for this tumor, with only a small number of patients studied to date. This is a case report of a dog with malignant melanoma that experienced a transient response to toceranib. Furthermore, the KIT expressed in the tumor of this case was examined using molecular analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A Shiba Inu dog presented with a gingival malignant melanoma extending into surrounding structures with metastasis to a submandibular lymph node. The dog was treated with toceranib (Palladia\u00ae; 2.6\u20132.9\u2009mg\/kg, orally, every other day) alone. Improvement of tumor-associated clinical signs (e.g., halitosis, tumor hemorrhage, trismus, and facial edema) with reduced size of the metastatic lymph node was observed on Day 15. The gingival tumor and associated masses in the masseter and pterygoid muscles decreased in size by Day 29 of treatment. Toceranib treatment was terminated on Day 43 due to disease progression and the dog died on Day 54. The tumor of this dog had a novel deletion mutation c.1725_1733del within\n                      <jats:italic>KIT<\/jats:italic>\n                      and the mutation caused ligand-independent phosphorylation of KIT, which was suppressed by toceranib. This mutation was considered to be an oncogenic driver mutation in the tumor of this dog, thereby explaining the anti-tumor activity of toceranib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This is the first report that presents a canine case of malignant melanoma that responded to toceranib therapy. KIT encoded by\n                      <jats:italic>KIT<\/jats:italic>\n                      harboring a mutation c.1725_1733del is a potential therapeutic target for toceranib in canine malignant melanoma. Further investigation of the\n                      <jats:italic>KIT<\/jats:italic>\n                      mutation status and toceranib therapy in canine malignant melanoma will need to be undertaken.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-021-02864-3","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T09:06:05Z","timestamp":1617786365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Hiroyuki","family":"Tani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunya","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Michishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Yayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-7730","authenticated-orcid":false,"given":"Makoto","family":"Bonkobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"3","key":"2864_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jsap.12624","volume":"58","author":"BN Sarowitz","year":"2017","unstructured":"Sarowitz BN, Davis GJ, Kim S. Outcome and prognostic factors following curative-intent surgery for oral tumours in dogs: 234 cases (2004 to 2014). J Small Anim Pract. 2017;58(3):146\u201353.","journal-title":"J Small Anim Pract"},{"issue":"9","key":"2864_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.2460\/javma.2001.218.1444","volume":"218","author":"KM Rassnick","year":"2001","unstructured":"Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989\u20132000). J Am Vet Med Assoc. 2001;218(9):1444\u20138.","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2864_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1476-5810.2005.00082.x","volume":"3","author":"S Murphy","year":"2005","unstructured":"Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H, Sparkes AH. Oral malignant melanoma \u2013 the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol. 2005;3(4):222\u20139.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"2864_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1476-5829.2012.00338.x","volume":"12","author":"G Dank","year":"2014","unstructured":"Dank G, Rassnick KM, Sokolovsky Y, Garrett LD, Post GS, Kitchell BE, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol. 2014;12(1):78\u201384.","journal-title":"Vet Comp Oncol"},{"issue":"11","key":"2864_CR5","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","volume":"15","author":"CA London","year":"2009","unstructured":"London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15(11):3856\u201365.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2864_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","volume":"100","author":"AT Liao","year":"2002","unstructured":"Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002;100(2):585\u201393.","journal-title":"Blood."},{"issue":"15","key":"2864_CR7","first-page":"5729","volume":"9","author":"NK Pryer","year":"2003","unstructured":"Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res. 2003;9(15):5729\u201334.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2864_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1476-5829.2010.00253.x","volume":"9","author":"A Murakami","year":"2011","unstructured":"Murakami A, Mori T, Sakai H, Murakami M, Yanai T, Hoshino Y, et al. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. Vet Comp Oncol. 2011;9(3):219\u201324.","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"2864_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tvjl.2012.09.005","volume":"196","author":"PY Chu","year":"2013","unstructured":"Chu PY, Pan SL, Liu CH, Lee J, Yeh LS, Liao AT. KIT gene exon 11 mutations in canine malignant melanoma. Vet J. 2013;196(2):226\u201330.","journal-title":"Vet J"},{"issue":"7","key":"2864_CR10","first-page":"2755","volume":"9","author":"CA London","year":"2003","unstructured":"London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9(7):2755\u201368.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2864_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1476-5829.2011.00265.x","volume":"10","author":"E Chon","year":"2012","unstructured":"Chon E, McCartan L, Kubicek LN, Vail DM. Safety evaluation of combination toceranib phosphate (palladia\u00ae) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Vet Comp Oncol. 2012;10(3):184\u201393.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"2864_CR12","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1111\/vco.12332","volume":"16","author":"RM Wouda","year":"2018","unstructured":"Wouda RM, Hocker SE, Higginbotham ML. Safety evaluation of combination carboplatin and toceranib phosphate (palladia) in tumour-bearing dogs: a phase I dose finding study. Vet Comp Oncol. 2018;16(1):E52\u201360.","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"2864_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/jsap.13111","volume":"61","author":"A Giuliano","year":"2020","unstructured":"Giuliano A, Dobson J. Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma. J Small Anim Pract. 2020;61(3):190\u20134.","journal-title":"J Small Anim Pract"},{"issue":"3","key":"2864_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","volume":"13","author":"SM Nguyen","year":"2015","unstructured":"Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176\u201383.","journal-title":"Vet Comp Oncol"},{"issue":"6","key":"2864_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/jvp.12816","volume":"42","author":"S Kurita","year":"2019","unstructured":"Kurita S, Miyamoto R, Tani H, Kobayashi M, Sasaki T, Tamura K, et al. Genetic alterations of KIT during clonal expansion and subsequent acquisition of resistance to toceranib in a canine mast cell tumor cell line. J Vet Pharmacol Ther. 2019;42(6):673\u201381.","journal-title":"J Vet Pharmacol Ther"},{"key":"2864_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1746-6148-9-190","volume":"9","author":"LF Bernabe","year":"2013","unstructured":"Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013;9:190.","journal-title":"BMC Vet Res"},{"issue":"1","key":"2864_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","volume":"23","author":"J Lennartsson","year":"2005","unstructured":"Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23(1):16\u201343.","journal-title":"Stem Cells"},{"issue":"1","key":"2864_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.V87.1.273.273","volume":"87","author":"T Tsujimura","year":"1996","unstructured":"Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, et al. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood. 1996;87(1):273\u201383.","journal-title":"Blood."},{"issue":"7","key":"2864_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-08-0067","volume":"6","author":"S Letard","year":"2008","unstructured":"Letard S, Yang Y, Hanssens K, Palm\u00e9rini F, Leventhal PS, Gu\u00e9ry S, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6(7):1137\u201345.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2864_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.tvjl.2012.11.018","volume":"196","author":"Y Takeuchi","year":"2013","unstructured":"Takeuchi Y, Fujino Y, Watanabe M, Takahashi M, Nakagawa T, Takeuchi A, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J. 2013;196(3):492\u20138.","journal-title":"Vet J"},{"issue":"2","key":"2864_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11259-016-9653-x","volume":"40","author":"I Gramer","year":"2016","unstructured":"Gramer I, Kessler M, Geyer J. Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma. Vet Res Commun. 2016;40(2):89\u201395.","journal-title":"Vet Res Commun"},{"key":"2864_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1746-6148-10-105","volume":"10","author":"CHC Halsey","year":"2014","unstructured":"Halsey CHC, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, et al. Development of an in vitro model of acquired resistance to toceranib phosphate (palladia\u00ae) in canine mast cell tumor. BMC Vet Res. 2014;10:105.","journal-title":"BMC Vet Res"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-021-02864-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T09:20:36Z","timestamp":1617787236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-02864-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2864"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-02864-3","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require official or institutional ethical approval as it was not experimental. The dog in this study was examined with the written consent of their owner.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The owner signed an informed consent form including the authorization to publish the data arising from this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}